Frequently asked questions
How this atlas selects entries, grades evidence, verifies claims, and communicates updates.
About the Atlas
What is the Peptides Community atlas?
It is a source-traceable research atlas covering peptide identity, evidence, safety signals, and regulatory status. Inclusion reflects scientific, clinical, regulatory, or public visibility and is not an endorsement of a substance or product.
Who maintains the atlas?
The atlas is maintained by an independent research team with backgrounds in pharmacology, chemistry, and regulatory science. Editorial decisions follow documented methodology and are reviewed for consistency.
How does the atlas select which peptides to include?
Compounds are selected based on documented clinical investigation, regulatory action, or sustained market visibility. Inclusion criteria are published in the scope and selection methodology.
Is the atlas medical advice?
No. The atlas is a research synthesis and does not provide individualized medical advice. Product status depends on the indication and jurisdiction, and research-use material must not be assumed safe, sterile, authentic, or suitable for humans.
Does the atlas recommend products or sellers?
No. Commercial listings may document that a claim or blend is marketed, but they cannot establish efficacy, safety, purity, or legal status. The atlas does not provide purchasing guidance or treat marketing claims as scientific evidence.
How can I join atlas updates?
Use the Join page to submit an email address. Updates are concise notes sent when peptide evidence, status, or source records change.
What is the difference between a peptide and a protein?
Peptides and proteins are both chains of amino acids linked by peptide bonds. The distinction is length: peptides typically contain fewer than 50 amino acids, while proteins have 50 or more. Some regulatory and scientific definitions use 40 amino acids as the cutoff. Longer chains fold into more complex three-dimensional structures.
How are peptides synthesized?
Peptides are synthesized through solid-phase peptide synthesis, a method where amino acids are sequentially added to a growing chain anchored to a resin support. After each addition, protecting groups prevent unwanted reactions. Once the full sequence is assembled, the peptide is cleaved from the resin and purified, typically by HPLC.
Can peptides be taken orally?
Most peptides have poor oral bioavailability because digestive enzymes in the stomach and small intestine break them down before they reach systemic circulation. Some are formulated with permeability enhancers or protective coatings for oral delivery, such as the GLP-1 agonist Rybelsus. Most peptide drugs must bypass the gastrointestinal tract.
Evidence & Grades
How does the atlas grade evidence?
The atlas grades each precise indication-specific claim from established evidence through preliminary human, preclinical, or marketing-only support, with a separate grade for contradictory evidence. A grade applies to the claim, not to the molecule as a whole.
What are the evidence grades A through E?
Grade A indicates established evidence from multiple consistent studies or official labeling. Grade B indicates preliminary human evidence. Grade C indicates preclinical evidence only. Grade D indicates marketing-only claims. Grade E indicates insufficient or no documented evidence.
What does the X grade mean?
The X grade marks contradictory evidence where available data conflict or where a well-designed study found no effect or negative outcomes for the specific claim.
How does the atlas verify claims?
Researchers prioritize current official records, product information, trial registries, and primary studies. Pages record search dates, identifiers, limitations, and source links. Approval, trial, sport, and legal-status claims are treated as time-sensitive and should be rechecked before decisions.
What sources does the atlas accept as evidence?
Acceptable sources include FDA and EMA official records, DailyMed and SmPC labels, PubMed-indexed studies, ClinicalTrials.gov records, and peer-reviewed systematic reviews. Commercial listings and social media posts are noted as marketing claims only.
What is the difference between GLP-1 and GIP?
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones secreted by the gut after food intake. GLP-1 stimulates insulin secretion, suppresses glucagon, and slows gastric emptying. GIP also stimulates insulin secretion and may influence bone metabolism and fat storage. Dual agonists targeting both receptors now exist.
Regulation & Status
Does an FDA-approved drug mean the same peptide from other sources is approved?
No. FDA approval applies to a specific drug product from a specific manufacturer for a specific indication. The same peptide sold by another supplier as a research chemical or compounding ingredient is not FDA-approved.
What does research-use-only status mean?
Research-use-only material is not approved for human administration. It has not been evaluated for safety, purity, sterility, or efficacy by any regulatory authority. Such products must not be assumed suitable for human use.
What does 'research use only' mean legally?
Research use only (RUO) indicates a product is labeled for laboratory or investigational purposes and has not undergone regulatory review for safety, efficacy, or manufacturing quality. RUO products cannot be marketed or intended for human administration. Selling RUO material for human use violates regulatory requirements in most jurisdictions including FDA and EMA rules.
How does compounding regulation affect peptides?
Compounding rules vary by jurisdiction. Some allow pharmacies to prepare peptide products from bulk substances under specific conditions; others prohibit it. The atlas documents each jurisdiction's compounding framework separately.
What is WADA status and why is it relevant?
WADA status indicates whether a substance is prohibited in sport. The atlas records the current WADA prohibited list category and any relevant monitoring program entries. This status is independent of medical approval.
Safety & Administration
How does the atlas document safety signals?
Safety signals are drawn from published adverse event reports, label warnings, clinical trial safety data, and regulatory communications. Each signal is linked to its source and graded by documentation quality.
Are contraindications and drug interactions recorded?
Yes, where documented in approved labeling or published studies. The atlas records contraindications, known interactions, and black-box warnings where applicable. Absence of a recorded interaction does not mean none exists.
What product-quality risks does the atlas cover?
The atlas covers risks related to authenticity, sterility, endotoxin contamination, incorrect potency, and stability failures. These are documented in the administration science section and in relevant monographs.
Should I rely on the atlas for preparation or administration instructions?
No. The atlas discusses concepts and documented risks but does not contain step-by-step preparation or administration steps. Only an approved product label is the authoritative source for those instructions.